EP1012333A1 - ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23 - Google Patents

ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23

Info

Publication number: EP1012333A1
Authority: EP; European Patent Office
Prior art keywords: cells; cell; seq; senescent; expression
Prior art date: 1997-08-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP98938406A

Other languages

English (en)

French (fr)

Other versions

EP1012333A4 (de

Inventor

Karen Swisshelm

Suzanne Hosier

Manfred Kubbies

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Washington

Original Assignee

University of Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-08

Filing date

1998-08-05

Publication date

2000-06-28

1998-08-05 Application filed by University of Washington filed Critical University of Washington

2000-06-28 Publication of EP1012333A1 publication Critical patent/EP1012333A1/de

2003-01-02 Publication of EP1012333A4 publication Critical patent/EP1012333A4/de

Status Withdrawn legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title description 75
238000002955 isolation Methods 0.000 title description 2
210000004027 cell Anatomy 0.000 claims abstract description 221
230000014509 gene expression Effects 0.000 claims abstract description 43
150000007523 nucleic acids Chemical class 0.000 claims abstract description 35
102000039446 nucleic acids Human genes 0.000 claims abstract description 34
108020004707 nucleic acids Proteins 0.000 claims abstract description 34
238000000034 method Methods 0.000 claims abstract description 29
239000013604 expression vector Substances 0.000 claims abstract description 17
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
229920001184 polypeptide Polymers 0.000 claims abstract description 14
239000012472 biological sample Substances 0.000 claims abstract description 6
102400000125 Cyclin-dependent kinase 5 activator 1, p25 Human genes 0.000 claims abstract 10
238000009396 hybridization Methods 0.000 claims description 38
239000002773 nucleotide Substances 0.000 claims description 24
125000003729 nucleotide group Chemical group 0.000 claims description 24
239000013598 vector Substances 0.000 claims description 22
210000002919 epithelial cell Anatomy 0.000 claims description 17
239000012634 fragment Substances 0.000 claims description 15
125000003275 alpha amino acid group Chemical group 0.000 claims description 14
230000009261 transgenic effect Effects 0.000 claims description 14
230000001105 regulatory effect Effects 0.000 claims description 12
230000027455 binding Effects 0.000 claims description 11
230000001939 inductive effect Effects 0.000 claims description 9
239000003153 chemical reaction reagent Substances 0.000 claims description 5
210000003527 eukaryotic cell Anatomy 0.000 claims description 5
238000003259 recombinant expression Methods 0.000 claims description 4
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
239000002853 nucleic acid probe Substances 0.000 claims description 2
230000009870 specific binding Effects 0.000 claims 2
230000009758 senescence Effects 0.000 abstract description 24
210000004748 cultured cell Anatomy 0.000 abstract description 10
102100024683 Ras-related protein R-Ras Human genes 0.000 description 191
239000000523 sample Substances 0.000 description 38
108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
108020004999 messenger RNA Proteins 0.000 description 30
239000002299 complementary DNA Substances 0.000 description 28
108020004414 DNA Proteins 0.000 description 25
235000018102 proteins Nutrition 0.000 description 24
102000004169 proteins and genes Human genes 0.000 description 24
206010028980 Neoplasm Diseases 0.000 description 22
210000001519 tissue Anatomy 0.000 description 19
238000000636 Northern blotting Methods 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 18
150000001413 amino acids Chemical class 0.000 description 18
238000004458 analytical method Methods 0.000 description 15
230000000694 effects Effects 0.000 description 15
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
201000011510 cancer Diseases 0.000 description 12
239000000074 antisense oligonucleotide Substances 0.000 description 11
238000012230 antisense oligonucleotides Methods 0.000 description 11
210000000349 chromosome Anatomy 0.000 description 11
210000004881 tumor cell Anatomy 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
208000026310 Breast neoplasm Diseases 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 8
238000003556 assay Methods 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000012010 growth Effects 0.000 description 8
239000011022 opal Substances 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 7
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000003211 malignant effect Effects 0.000 description 7
239000003226 mitogen Substances 0.000 description 7
229930002330 retinoic acid Natural products 0.000 description 7
229960001727 tretinoin Drugs 0.000 description 7
108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000001574 biopsy Methods 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
108090000601 Claudin-4 Proteins 0.000 description 5
108090000582 Claudin-5 Proteins 0.000 description 5
108020004635 Complementary DNA Proteins 0.000 description 5
108091060211 Expressed sequence tag Proteins 0.000 description 5
102000005936 beta-Galactosidase Human genes 0.000 description 5
108010005774 beta-Galactosidase Proteins 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000006870 function Effects 0.000 description 5
230000005714 functional activity Effects 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000002062 proliferating effect Effects 0.000 description 5
230000008707 rearrangement Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
102100038447 Claudin-4 Human genes 0.000 description 4
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000005260 human cell Anatomy 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
230000004044 response Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108091034057 RNA (poly(A)) Proteins 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
108091023045 Untranslated Region Proteins 0.000 description 3
230000032683 aging Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000002759 chromosomal effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
-1 i.e. Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
230000002028 premature Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000011285 therapeutic regimen Methods 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
108091005703 transmembrane proteins Proteins 0.000 description 3
102000035160 transmembrane proteins Human genes 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
102000004057 Claudin-5 Human genes 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000032823 cell division Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000008711 chromosomal rearrangement Effects 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
238000004590 computer program Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
210000003917 human chromosome Anatomy 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000010354 integration Effects 0.000 description 2
206010024627 liposarcoma Diseases 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000001360 synchronised effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000005945 translocation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
230000005760 tumorsuppression Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
241001479434 Agfa Species 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
241000274965 Cyrestis thyodamas Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102100030708 GTPase KRas Human genes 0.000 description 1
101710113436 GTPase KRas Proteins 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 1
101001082860 Homo sapiens Peroxisomal membrane protein 2 Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101150038744 PMP22 gene Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000005877 Peptide Initiation Factors Human genes 0.000 description 1
108010044843 Peptide Initiation Factors Proteins 0.000 description 1
102100030564 Peroxisomal membrane protein 2 Human genes 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
108090000244 Rat Proteins Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
230000018199 S phase Effects 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000000069 breast epithelial cell Anatomy 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000010094 cellular senescence Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013601 cosmid vector Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000004955 epithelial membrane Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002795 fluorescence method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
208000001749 optic atrophy Diseases 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
150000004713 phosphodiesters Chemical group 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000003716 rejuvenation Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000008943 replicative senescence Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003994 retinal ganglion cell Anatomy 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical class OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000037351 starvation Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000000225 tumor suppressor protein Substances 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

This enzyme's presence can be detected easily by providing cells with a substrate that yields a blue-colored product upon enzymatic cleavage.
these investigators observed an age-dependent rise in this senescence-associated ⁇ -galactosidase in human skin, suggesting that the accumulation of the enzyme provides a marker for senescence in fibroblasts and keratinocytes in the skin and perhaps other epithelial tissues.
senescence may have evolved as a mechanism for tumor suppression, and that aging is an indirect effect of this circumstance. Because constraints on growth control are absent from tumor cells, such cells most likely have switched off the expression of genes whose products promote or maintain the senescent state. For example, in vitro studies have indicated that senescence can be partially circumvented by the inactivation of tumor suppressor proteins such as the retinoblastoma tumor suppressor gene RBI (Weinberg, Cell 81:323-330, 1995). This suggests the possibility that the loss of functional tumor suppressor genes in vivo could permit cells to gain a replicative advantage and eventually to undergo immortalization.
tumor suppressor proteins such as the retinoblastoma tumor suppressor gene RBI (Weinberg, Cell 81:323-330, 1995). This suggests the possibility that the loss of functional tumor suppressor genes in vivo could permit cells to gain a replicative advantage and eventually to undergo immortalization.
a novel gene has been identified that is expressed at high levels in senescent cells.
a cDNA corresponding to the novel gene has been isolated and sequenced and found to contain an open reading frame encoding a protein having a deduced molecular weight of 23 kilodaltons (kDa) (SEQ ID NO: l).
kDa kilodaltons
this gene has been named "p23.”
Messenger RNA transcribed from p23 is reproducibly detectable at higher levels in senescent than in proliferating cultured normal human mammary epithelial cells.
p23 The function of p23 is not known, but analysis of its deduced amino acid sequence (SEQ ID NO:2) suggests that it belongs to a family of transmembrane proteins known as the "PMP 22" family or "epithelial membrane protein” (EMP) family (e.g., see Taylor et al., J. Biol. Chem. 270:28824-28833, 1995; Lobsiger et al., Genomics 36:379-387, 1996; Taylor and Suter, Gene 175:115-120. 1996).
PMP 22 family
EMP epidermal membrane protein
Immunospecific reagents capable of specifically binding p23 may be produced by hybridoma or by repeated injection of the purified protein or selected peptides derived from p23 in combination with an appropriate adjuvant (e.g., Freund's, ISCOMs, or the like) into a suitable animal such as a rabbit, sheep, or goat.
an appropriate adjuvant e.g., Freund's, ISCOMs, or the like
Therapeutic applications include binding partners that inhibit the binding of p23 to ligands that normally bind to it. thus promoting cell proliferation in the treated cell.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Crystallography & Structural Chemistry (AREA)
Microbiology (AREA)
Immunology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP98938406A 1997-08-08 1998-08-05 ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23 Withdrawn EP1012333A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US90887397A	1997-08-08	1997-08-08
US908873		1997-08-08
PCT/US1998/016343 WO1999007893A1 (en)	1997-08-08	1998-08-05	ISOLATION OF A NOVEL SENESCENCE-FACTOR GENE, p23

Publications (2)

Publication Number	Publication Date
EP1012333A1 true EP1012333A1 (de)	2000-06-28
EP1012333A4 EP1012333A4 (de)	2003-01-02

Family

ID=25426353

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP98938406A Withdrawn EP1012333A4 (de)	1997-08-08	1998-08-05	ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23

Country Status (9)

Country	Link
EP (1)	EP1012333A4 (de)
JP (1)	JP2001512698A (de)
KR (1)	KR20010022741A (de)
CN (1)	CN1270637A (de)
AU (1)	AU8693598A (de)
BR (1)	BR9811865A (de)
CA (1)	CA2296598A1 (de)
TR (1)	TR200000331T2 (de)
WO (1)	WO1999007893A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7202352B2 (en)	2000-01-21	2007-04-10	Polymun Scientific Immunbiologische Forschung Gmbh	Tumor and senescence marker
AU750296B2 (en)	2000-06-23	2002-07-11	F. Hoffmann-La Roche Ag	Antibodies against SEMP1, methods for their production and uses thereof
CA2421249A1 (en) *	2000-09-20	2002-03-28	Human Genome Sciences, Inc.	21 human secreted proteins
WO2002101075A2 (en)	2001-06-13	2002-12-19	Millennium Pharmaceuticals, Inc.	Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
MX2010012473A (es)	2008-05-23	2011-02-23	Siwa Corp	Metodos, composiciones y aparato para facilitar la regeneracion.
EP3511017A1 (de)	2010-09-27	2019-07-17	Siwa Corporation	Selektive entfernung von altersmodifizierten zellen zur behandlung von atherosklerose
US8721571B2 (en)	2010-11-22	2014-05-13	Siwa Corporation	Selective removal of cells having accumulated agents
US10584180B2 (en)	2014-09-19	2020-03-10	Siwa Corporation	Anti-AGE antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en)	2014-12-18	2018-06-12	Siwa Corporation	Method and composition for treating sarcopenia
US10358502B2 (en)	2014-12-18	2019-07-23	Siwa Corporation	Product and method for treating sarcopenia
EP3677598B1 (de)	2016-02-19	2022-04-06	Siwa Corporation	Verfahren und zusammensetzung zur behandlung von krebs, abtötung von metastasierenden krebszellen und verhinderung von krebsmetastasen mit einem antikörper gegen fortgeschrittene glykierungsendprodukte
WO2017181116A1 (en)	2016-04-15	2017-10-19	Siwa Corporation	Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en)	2016-06-23	2017-12-28	Siwa Corporation	Vaccines for use in treating various diseases and disorders
US10858449B1 (en)	2017-01-06	2020-12-08	Siwa Corporation	Methods and compositions for treating osteoarthritis
US10995151B1 (en)	2017-01-06	2021-05-04	Siwa Corporation	Methods and compositions for treating disease-related cachexia
US10961321B1 (en)	2017-01-06	2021-03-30	Siwa Corporation	Methods and compositions for treating pain associated with inflammation
US10925937B1 (en)	2017-01-06	2021-02-23	Siwa Corporation	Vaccines for use in treating juvenile disorders associated with inflammation
BR112019021471A2 (pt)	2017-04-13	2020-05-12	Siwa Corporation	Anticorpo monoclonal humanizado de produto final da glicação avançada
US11518801B1 (en)	2017-12-22	2022-12-06	Siwa Corporation	Methods and compositions for treating diabetes and diabetic complications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996013610A2 (en) *	1994-10-31	1996-05-09	Geron Corporation	Methods and reagents for the identification and regulation of senescence-related genes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5580726A (en) *	1994-04-29	1996-12-03	Geron Corporation	Method and Kit for enhanced differential display
WO1999007850A1 (en) *	1997-08-06	1999-02-18	Millennium Biotherapeutics, Inc.	Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides
ES2312205T3 (es) *	1998-03-10	2009-02-16	Genentech, Inc.	Nuevo polipeptido y acidos nucleicos que lo codifican.
JP2002519029A (ja) *	1998-06-29	2002-07-02	インサイト・ファーマスーティカルズ・インコーポレイテッド	アポトーシス関連分子

1998
- 1998-08-05 CN CN98807887A patent/CN1270637A/zh active Pending
- 1998-08-05 AU AU86935/98A patent/AU8693598A/en not_active Abandoned
- 1998-08-05 KR KR1020007001338A patent/KR20010022741A/ko not_active Application Discontinuation
- 1998-08-05 BR BR9811865-0A patent/BR9811865A/pt not_active Application Discontinuation
- 1998-08-05 WO PCT/US1998/016343 patent/WO1999007893A1/en active Search and Examination
- 1998-08-05 TR TR2000/00331T patent/TR200000331T2/xx unknown
- 1998-08-05 EP EP98938406A patent/EP1012333A4/de not_active Withdrawn
- 1998-08-05 JP JP2000506375A patent/JP2001512698A/ja not_active Withdrawn
- 1998-08-05 CA CA002296598A patent/CA2296598A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996013610A2 (en) *	1994-10-31	1996-05-09	Geron Corporation	Methods and reagents for the identification and regulation of senescence-related genes

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] 211 aa, 15 June 1999 (1999-06-15) "Human Tango-73 protein" retrieved from EBI Database accession no. AAY04143 XP002217495 -& WO 99 07850 A 18 February 1999 (1999-02-18) *
DATABASE EMBL [Online] 211 aa, 7 December 1999 (1999-12-07) "Human PRO944 protein sequence" retrieved from EBI Database accession no. AAY41726 XP002217497 -& WO 99 46281 A 16 September 1999 (1999-09-16) *
DATABASE EMBL [Online] 2747 bp, 7 December 1999 (1999-12-07) "Human PRO944 nucleotide sequence" retrieved from EBI Database accession no. AAZ34118 XP002217498 -& WO 99 46281 A 16 September 1999 (1999-09-16) *
DATABASE EMBL [Online] 3400 pb, 5 May 2000 (2000-05-05) "cDNA encoding a human molecule associated with apoptosis 2 (MAPOP-2)" retrieved from EBI Database accession no. AAZ60459 XP002217494 & WO 00 00609 A 6 January 2000 (2000-01-06) *
DATABASE EMBL [Online] 3483 pb, 15 June 1999 (1999-06-15) "Human Tango-73 encoding cDNA" retrieved from EBI Database accession no. AAX19956 XP002217496 -& WO 99 07850 A 18 February 1999 (1999-02-18) *
DATABASE EMBLLEVANT [Online] 211 aa, 5 May 2000 (2000-05-05) "A human molecule associated with apoptosis 2 (MAPOP-2)" retrieved from EBI Database accession no. AAY68679 XP002217493 -& WO 00 00609 A 6 January 2000 (2000-01-06) *
FURUSE M ET AL: "CLAUDIN-1 AND -2: NOVEL INTEGRAL MEMBRANE PROTEINS LOCALIZING AT TIGHT JUNCTIONS WITH NO SEQUENCE SIMILARITY TO OCCLUDIN" JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 141, no. 7, 29 June 1998 (1998-06-29), pages 1539-1550, XP001008152 ISSN: 0021-9525 *
JONASDOTTIR A. ET AL.: "Refinement of the dominant optic atrophy locus (OPA1) to a 1.4-cM interval on chromosome 3q28-3q29 within a 3-Mb YAC contig" ORIGINAL INVESTIGATION, vol. 99, 1997, pages 115-120, XP002217491 *
LINSKENS M H K ET AL: "CATALOGING ALTERED GENE EXPRESSION IN YOUNG AND SENESCENT CELLS USING ENHANCED DIFFERENTIAL DISPLAY" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 23, no. 16, 1995, pages 3244-3251, XP002047039 ISSN: 0305-1048 *
See also references of WO9907893A1 *
SMITH D. ET AL.: "Localization of 616 human chromosome 3-specific cosmids using a somatic cell hybrid deletion mapping panel" GENOMICS, vol. 11, September 1991 (1991-09), pages 179-187, XP001107125 *
SWISSHELM K ET AL: "SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 226, no. 2, 21 January 1999 (1999-01-21), pages 285-295, XP004155143 ISSN: 0378-1119 *

Also Published As

Publication number	Publication date
WO1999007893A1 (en)	1999-02-18
KR20010022741A (ko)	2001-03-26
BR9811865A (pt)	2000-08-15
JP2001512698A (ja)	2001-08-28
EP1012333A4 (de)	2003-01-02
CA2296598A1 (en)	1999-02-18
TR200000331T2 (tr)	2000-05-22
CN1270637A (zh)	2000-10-18
AU8693598A (en)	1999-03-01

Publication	Publication Date	Title
EP1012333A1 (de)	2000-06-28	ISOLIERUNG EINES NEUEN ALTERUNGSFAKTOR-GENS, p23
JP3871339B2 (ja)	2007-01-24	脊椎動物アポトーシス遺伝子：組成物および方法
WO1996002552A1 (en)	1996-02-01	Lung cancer marker
WO2003101388A2 (en)	2003-12-11	Human solute carrier family 7 member 11 (hslc7a11)
Fernandez-Pol et al.	1993	A growth factor-inducible gene encodes a novel nuclear protein with zinc finger structure.
JP2002525067A (ja)	2002-08-13	レプチン誘導遺伝子
JP2003508030A (ja)	2003-03-04	新規ポリペプチドおよびそれをコードする核酸
EP1048727B1 (de)	2006-05-17	Gen, welches für neues transmembranprotein kodiert
US6987004B1 (en)	2006-01-17	Genes integrating signal transduction pathways
KR100869190B1 (ko)	2008-11-18	암세포 증식 조절에 유용한 폴리뉴클레오티드
WO2001038523A1 (fr)	2001-05-31	Nouveau polypeptide, gene humain 14 lie a la surdite, et polynucleotide codant pour ce polypeptide
US6586581B1 (en)	2003-07-01	Prolactin regulatory element binding protein and uses thereof
US20050196753A1 (en)	2005-09-08	Human coactivator-associated arginine methyltransferase 1 (hCARM1)
AU762987B2 (en)	2003-07-10	Chondrosarcoma associated genes
AU776341B2 (en)	2004-09-02	Meg-1 protein
JP2006525031A (ja)	2006-11-09	Ａｃｈｅｒｏｎ発現の制御方法
AU2319700A (en)	2000-08-18	Meg-4 protein
US6342594B1 (en)	2002-01-29	Nucleic acid which is upregulated in metastatic human tumor cells
US7309783B2 (en)	2007-12-18	Mammalian early developmental regulator gene
WO2002026809A1 (fr)	2002-04-04	Nouveau polypeptide, proteine transmembranaire 35.31 possedant un domaine permettant la duplication de facteurs de croissance epidermique, et polynucleotide codant ce polypeptide
WO2001021649A2 (en)	2001-03-29	Nucleic acids encoding vitamin d response element binding proteins, products related thereto, and methods of using same
US20030109016A1 (en)	2003-06-12	TSLL1 gene
US20020123092A1 (en)	2002-09-05	Regulatory elements from RP1 gene and uses thereof
Mattei et al.	0	Human CREM Gene: Evolutionary Conservation, Chromosomal Localization, and Inducibility of the Transcript’
WO2001049734A1 (fr)	2001-07-12	Nouveau polypeptide, proteine plp 10, et polynucleotide codant pour ce polypeptide

Legal Events

Date	Code	Title	Description
2000-05-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-06-28	17P	Request for examination filed	Effective date: 20000125
2000-06-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
2003-01-02	A4	Supplementary search report drawn up and despatched	Effective date: 20021113
2003-01-02	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
2003-06-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2003-08-06	18D	Application deemed to be withdrawn	Effective date: 20030116